Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The 2014 outbreak of Ebola virus disease in West Africa has highlighted the need for the availability of effective vaccines against outbreak pathogens that are suitable for use in frontline workers who risk their own health in the course of caring for those with the disease, and also for members of the community in the affected area. Along with effective contact tracing and quarantine, use of a vaccine as soon as an outbreak is identified could greatly facilitate rapid control and prevent the outbreak from spreading. This review describes the progress that has been made in producing and testing adenovirus-based Ebola vaccines in both pre-clinical and clinical studies, and considers the likely future use of these vaccines.

Original publication

DOI

10.1586/14760584.2015.1077122

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

2015

Volume

14

Pages

1347 - 1357

Keywords

Ebola virus disease, clinical trials, outbreak pathogen, replication-deficient adenoviral vector, response to vaccination, simian adenoviral vector, vaccination, Adenoviridae, Africa South of the Sahara, Antibodies, Neutralizing, Antibodies, Viral, Disease Outbreaks, Ebola Vaccines, Ebolavirus, Hemorrhagic Fever, Ebola, Humans, Vaccination